Investment Bank Reiterates 'Buy' Rating For Therapeutics Company
Spero Therapeutics: A Biotech Investment Opportunity That You Shouldn't Miss.
In the ever-evolving world of biotechnology, one company that has recently caught the attention of investors and industry analysts alike is Spero Therapeutics (NASDAQ: $SPRO). HC Wainwright & Co., a reputable full-service investment bank, has reiterated its 'Buy' rating on the company's stock and maintained a price target of $7. This not only indicates the firm's confidence in Spero's potential but also suggests a significant upside potential from the current trading levels around $1.70. $Spero Therapeutics (SPRO.US)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
